Biossil
Toronto, CA · 7 known investors
biossil is an AI-native biopharma company developing late-stage drug programs for life-threatening conditions with unmet needs, including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. It applies gene embedding analysis to drug discovery, rescue, and repositioning, with active and planned clinical trials across a range of rare and severe indications.
Founders & leadership
AI
Alexander I. MosaMD PhD
AM
Anthony MouchantafJD MBA
Investors · 7
Funding
SEC filings, press & company announcements$3.7M disclosed across 1 round · 2026
- $3.7MseedApr 2026
Golden Ventures, Staircase Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Biossil do?
- biossil is an AI-native biopharma company developing late-stage drug programs for life-threatening conditions with unmet needs, including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. It applies gene embedding analysis to drug discovery, rescue, and repositioning, with active and planned clinical trials across a range of rare and severe indications.
- Who founded Biossil?
- Biossil was founded by Alexander I. Mosa, Anthony Mouchantaf.
- Who are Biossil's investors?
- Biossil's investors include Founders Fund, Golden Ventures, Panache Ventures, Staircase Ventures, 137 Ventures, DRI Healthcare, Quiet Capital.
- How much funding has Biossil raised?
- Biossil has disclosed $3.7M raised across 1 round.
- Where is Biossil headquartered?
- Biossil is headquartered in Toronto, CA.